Kagocel® entered the TOP-20 of the Russian pharmacy market
14.11.2023
According to the analytical agency DSM Group for September 2023, the modern antiviral Kagocel®, manufactured by Binnopharm Group, entered the TOP-20 drugs of the Russian pharmacy market by sales in rubles. The drug moved up to the 18th rank, adding 110 places comparing to the previous period.
The sales volume of the drug in the reporting period by value amounted to RUB 513 mio, showing the maximum growth of 166.1 % (month-over-month) among other drugs.
Ekaterina Slavgorodskaya, Sales and Promotion Director of Binnopharm Group: «Kagocel® has been the focus brand for Binnopharm Group during the past two years. In 2023, the drug has been showing sales growth and impressive momentum despite the seasonal market decline. Its success is caused by its clinically proven efficacy, the right promotion strategy, and our team effords».
In 2023, Kagocel® became the winner of the annual Smartpharma® Awards in the category «Antiviral No. 1 against influenza and other acute respiratory viral infections with the possibility of delayed treatment».
The sales volume of the drug in the reporting period by value amounted to RUB 513 mio, showing the maximum growth of 166.1 % (month-over-month) among other drugs.
Ekaterina Slavgorodskaya, Sales and Promotion Director of Binnopharm Group: «Kagocel® has been the focus brand for Binnopharm Group during the past two years. In 2023, the drug has been showing sales growth and impressive momentum despite the seasonal market decline. Its success is caused by its clinically proven efficacy, the right promotion strategy, and our team effords».
In 2023, Kagocel® became the winner of the annual Smartpharma® Awards in the category «Antiviral No. 1 against influenza and other acute respiratory viral infections with the possibility of delayed treatment».
